Mainstream Biotech is an innovative peptide drug developer. The company has developed a series of peptide drugs with a class of new drug potential using its advanced and unique peptide drug conjugate (PDC) and multifunctional peptide drug screening and optimization platform. At present, the company has branches in Zhongshan, Shanghai and the United States to jointly promote the global research and development process of new peptide drugs. Recently, Mainstream Biotech completed a Series A financing of nearly 100 million yuan. This round of financing was led by Fuhui Ventures, followed by a number of institutions such as Tanxue Capital and Dingfu Investment. The funds raised will be used to build the company’s core technology platform and promote clinical research on key R&D pipelines.
This article is reproduced from: https://www.itjuzi.com/investevent/13654645
This site is for inclusion only, and the copyright belongs to the original author.